Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07960613 + quadrivalent influenza vaccine
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
PF-07960613 + quadrivalent influenza vaccine is a combination vaccine regimen developed by Pfizer. It consists of PF-07960613—a bivalent combination of the mRNA-based COVID-19 vaccine (BNT162b2; Comirnaty) and the recombinant RSV prefusion F protein subunit vaccine (RSVpreF; Abrysvo)—co-administered with a licensed quadrivalent influenza vaccine (QIV). The regimen was designed to provide comprehensive seasonal protection against three major respiratory viruses: SARS-CoV-2, Respiratory Syncytial Virus (RSV), and Influenza A and B. It was evaluated in Phase 2 clinical trials in healthy adults aged 65 and older to assess safety, tolerability, and immunogenicity. In July 2024, Pfizer announced the discontinuation of the PF-07960613 combination program, although the individual component vaccines remain available for their respective indications.
- Brand names
- AbrysvoComirnaty
- Other names
- Pfizer COVID-19-RSV-flu combination
02
Targets
HA0 (Influenza B virus hemagglutinin)RSV F (Respiratory syncytial virus fusion protein)SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on PF-07960613 + quadrivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07960613 + quadrivalent influenza vaccine.